Please use this identifier to cite or link to this item:
Title: Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study.
Author: Martínez Castelao, Alberto
Cases Amenós, A. (Aleix)
Torre Carballada, Alberto
Torralba Iranzo, Alberto
Bronsoms, Josep
Vallés Prat, Martí
Torán, Daniel
Masso Jimenez, Elisabet
Investigators of the ACERCA Study Group
Keywords: Anèmia
Insuficiència renal crònica
Assaigs clínics
Chronic renal failure
Clinical trials
Issue Date: 23-Jun-2015
Publisher: Elsevier España
Abstract: BACKGROUND AND OBJECTIVE: The Anemia Working Group of ERBP in 2010 recommended a target hemoglobin (Hb) level in the range of 11-12 g/dL, without intentionally exceeding 13 g/dL during the treatment with erythropoiesis stimulating agents (ESAs). This study evaluated if there was a clinical impact of this statement in the anemia management of chronic kidney disease (CKD) patients treated with ESAs not on dialysis in routine clinical practice in Spain. METHODS: This was an observational and cross-sectional study carried out in CKD patients not on dialysis in Spain who initiated ESA treatment (naïve), or were shifted from a previous ESA to another ESAs (converted) since January 2011. RESULTS: Of 441 patients evaluated, 67.6% were naïve and 32.4% were converted. At the study visit, 42.5% of naïve patients achieved the Hb target of 11-12 g/dL, with a mean Hb of 11.3±1.3 g/dL (vs 10.1±0.9 g/dL at the start of ESA therapy). Only 35.3% of converted patients maintained Hb levels within the recommended target at the study visit. Yet, 8.2% of naïve patients and 7.9% of those converted had Hb levels >13 g/dL. Hb levels were similar across subgroups of patients, regardless of the presence of significant comorbidities. CONCLUSIONS: Anemia management in CKD patients treated with ESAs by Spanish nephrologists seems to be aimed at preventing Hb levels <11 g/dL, while <50% of patients were within the narrow recommended Hb target range. This, together with the lack of individualization in Hb targets according to patients' comorbidities show that there is still room for improvement in renal anemia management in the clinical setting.
Note: Reproducció del document publicat a:
It is part of: Nefrología, 2015, vol. 35, num. 2, p. 179-188
Related resource:
ISSN: 0211-6995
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
653759.pdf213.27 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons